Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Mesenchymal stem cells expressing vasoactive intestinal peptide ameliorate symptoms in a model of chronic multiple sclerosis.
Gap junction pathology in multiple sclerosis lesions and normal-appearing white matter.
In vivo evidence of glutamate toxicity in multiple sclerosis.
Incidence of multiple sclerosis in Northern Lisbon, Portugal: 1998¿2007.
Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
Flow cytometric analysis of cerebrospinal fluid samples and its usefulness in routine clinical practice.
The environment and disease: association or causation?
Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients.
Quantitative assessment of multiple sclerosis using inertial sensors and the TUG test.
Cytokine profile in relapsing‑remitting multiple sclerosis patients and the association between progression and activity of the disease.
Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects.
Plasma exchange in severe attacks of neuromyelitis optica.
Fulminant Central Nervous System Nocardiosis in a Patient Treated With Alemtuzumab For Relapsing-Remitting Multiple Sclerosis.
Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab.
Modulation of Sox10, HIF-1α, Survivin, and YAP by Minocycline in the Treatment of Neurodevelopmental Handicaps following Hypoxic Insult.
A major histocompatibility Class I locus contributes to multiple sclerosis susceptibility independently from HLA-DRB1*15:01.
Abnormalities of Motor Imagery and Relationship With Depressive Symptoms in Mildly Disabling Relapsing-Remitting Multiple Sclerosis.
Unraveling the secrets of white matter - Bridging the gap between cellular, animal and human imaging studies.
Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases.
The risk of multiple sclerosis in bereaved parents: A nationwide cohort study in Denmark.
Microbial colonization influences early B-lineage development in the gut lamina propria.
Multiple sclerosis: Does aggressive MS warrant aggressive treatment?
T cells become licensed in the lung to enter the central nervous system.
Pelvic Floor Muscle Training With and Without Electrical Stimulation in the Treatment of Lower Urinary Tract Symptoms in Women With Multiple Sclerosis.
Pages
« first
‹ previous
…
114
115
116
117
118
119
120
121
122
…
next ›
last »